Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Intentional product misuse? 632 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 632 reports of Intentional product misuse have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.6% of all adverse event reports for TOCILIZUMAB.

632
Reports of Intentional product misuse with TOCILIZUMAB
0.6%
of all TOCILIZUMAB reports
196
Deaths
148
Hospitalizations

How Dangerous Is Intentional product misuse From TOCILIZUMAB?

Of the 632 reports, 196 (31.0%) resulted in death, 148 (23.4%) required hospitalization, and 88 (13.9%) were considered life-threatening.

Is Intentional product misuse Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 632 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Intentional product misuse?

ETANERCEPT (3,992) PREGABALIN (3,731) BUDESONIDE\FORMOTEROL (3,399) ACETAMINOPHEN (2,924) ESOMEPRAZOLE (2,852) MINOXIDIL (2,418) TOFACITINIB (2,331) CINACALCET (2,092) QUETIAPINE (1,855) ALPRAZOLAM (1,709)

Which TOCILIZUMAB Alternatives Have Lower Intentional product misuse Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Intentional product misuse Reports All Drugs Causing Intentional product misuse TOCILIZUMAB Demographics